利雅得国王医疗城支持异基因造血祖细胞移植受者的血液和血液制品——输血医疗服务

Q4 Medicine
A. Al Harbi, A. Al-Anazi, Faisal Al Saqri, Haya Wasel
{"title":"利雅得国王医疗城支持异基因造血祖细胞移植受者的血液和血液制品——输血医疗服务","authors":"A. Al Harbi, A. Al-Anazi, Faisal Al Saqri, Haya Wasel","doi":"10.4103/joah.joah_115_21","DOIUrl":null,"url":null,"abstract":"Hematopoietic progenitor cell transplant (HPCT) is found throughout the body. HPCT is a set of undifferentiated cells that are capable of indefinite self-renewal and generation of a functional progeny of highly specialized cells. Allogeneic HPCT presents a distinct set of challenges for blood banks and transfusion services. When considering transfusion for an HPCT recipient, one has to take into account not only the complexities associated with the patient's underlying condition, but also potential problems associated with recipient alloantibodies, donor passenger lymphocytes, and the conversion of blood group substance after successful allogeneic HPCT. For an allogeneic HPCT recipient, it is vital that the blood transfusion service keep a detailed record of the donor and recipient's that include donor blood group and antibody screening results and recipient's pre- and posttransplant blood group and antibody screening results. The management of nonidentical and incompatible HPCT requires a unique strategies when major, minor, and bidirectional differences exist which have the potentiality to improve patient outcomes and allow for effective management of the blood and blood products inventory.","PeriodicalId":36501,"journal":{"name":"Journal of Applied Hematology","volume":"13 1","pages":"172 - 175"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Blood and blood products to support allogeneic hematopoietic progenitor cell transplant recipients at king abdulaziz medical city-Riyadh – Transfusion medicine services\",\"authors\":\"A. Al Harbi, A. Al-Anazi, Faisal Al Saqri, Haya Wasel\",\"doi\":\"10.4103/joah.joah_115_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hematopoietic progenitor cell transplant (HPCT) is found throughout the body. HPCT is a set of undifferentiated cells that are capable of indefinite self-renewal and generation of a functional progeny of highly specialized cells. Allogeneic HPCT presents a distinct set of challenges for blood banks and transfusion services. When considering transfusion for an HPCT recipient, one has to take into account not only the complexities associated with the patient's underlying condition, but also potential problems associated with recipient alloantibodies, donor passenger lymphocytes, and the conversion of blood group substance after successful allogeneic HPCT. For an allogeneic HPCT recipient, it is vital that the blood transfusion service keep a detailed record of the donor and recipient's that include donor blood group and antibody screening results and recipient's pre- and posttransplant blood group and antibody screening results. The management of nonidentical and incompatible HPCT requires a unique strategies when major, minor, and bidirectional differences exist which have the potentiality to improve patient outcomes and allow for effective management of the blood and blood products inventory.\",\"PeriodicalId\":36501,\"journal\":{\"name\":\"Journal of Applied Hematology\",\"volume\":\"13 1\",\"pages\":\"172 - 175\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Applied Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/joah.joah_115_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joah.joah_115_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

造血祖细胞移植(HPCT)遍布全身。HPCT是一组未分化的细胞,能够无限期自我更新并产生高度特化细胞的功能性后代。异基因HPCT对血库和输血服务提出了一系列独特的挑战。当考虑为HPCT接受者输血时,不仅必须考虑与患者潜在疾病相关的复杂性,还必须考虑与接受者同种异体抗体、供体乘客淋巴细胞和成功同种异体HPCT后血型物质转化相关的潜在问题。对于异基因HPCT受体,输血服务部门必须详细记录供体和受体的情况,包括供体血型和抗体筛查结果以及受体移植前后的血型和抗体筛选结果。当存在主要、次要和双向差异时,不相同和不兼容的HPCT的管理需要独特的策略,这些差异有可能改善患者的预后,并允许对血液和血液制品库存进行有效管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Blood and blood products to support allogeneic hematopoietic progenitor cell transplant recipients at king abdulaziz medical city-Riyadh – Transfusion medicine services
Hematopoietic progenitor cell transplant (HPCT) is found throughout the body. HPCT is a set of undifferentiated cells that are capable of indefinite self-renewal and generation of a functional progeny of highly specialized cells. Allogeneic HPCT presents a distinct set of challenges for blood banks and transfusion services. When considering transfusion for an HPCT recipient, one has to take into account not only the complexities associated with the patient's underlying condition, but also potential problems associated with recipient alloantibodies, donor passenger lymphocytes, and the conversion of blood group substance after successful allogeneic HPCT. For an allogeneic HPCT recipient, it is vital that the blood transfusion service keep a detailed record of the donor and recipient's that include donor blood group and antibody screening results and recipient's pre- and posttransplant blood group and antibody screening results. The management of nonidentical and incompatible HPCT requires a unique strategies when major, minor, and bidirectional differences exist which have the potentiality to improve patient outcomes and allow for effective management of the blood and blood products inventory.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Applied Hematology
Journal of Applied Hematology Medicine-Hematology
CiteScore
0.40
自引率
0.00%
发文量
34
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信